T-cells Archives

Podcast 8 Sep 2023

Beyond Biotech podcast 62 – cytokine-based drugs

As September 8 is Stand Up To Cancer Day, one area of promising research lies in cytokine-based drugs, which have the potential to activate T cells against tumors. Historically, toxicity…

September 8, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 20 Jul 2023

CatalYm shows importance of GDF-15 in tumor immunotherapy resistance

CatalYm has published preclinical data in Nature Communications that reveal the central role of Growth Differentiation Factor-15 (GDF-15) in the resistance of tumors to current immunotherapy. CatalYm said the findings…

July 20, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 7 Jul 2023

CytoMed Therapeutics receives US patent for CAR-Gamma Delta T-cell technology

CytoMed Therapeutics Limited, a Singapore-based biopharma company focused on novel donor cell-based immunotherapies for the treatment of various cancers, has announced that its CAR-gamma delta T cell (CAR-γδ T cell)…

July 7, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 21 Jun 2023

FDA clears T-Cell receptor natural killer cell therapy for sarcoma

Replay, a genome writing company, and The University of Texas MD Anderson Cancer Center (MD Anderson), have announced that the U.S. Food & Drug Administration (FDA) has issued a ‘safe…

June 21, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 1 Jun 2023

Sanofi drug reduces disease activity in relapsing MS

New data, being presented in a late-breaking session at the 2023 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, demonstrate that frexalimab, Sanofi’s novel second-generation investigational anti-CD40L antibody, with a…

June 1, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 16 May 2023

LabGenius looks to create molecules with huge increase in tumor killing ability

LabGenius, which uses machine learning (ML) for antibody discovery, has presented data in a poster presentation at the Protein Engineering and Biotherapeutics (PEGS) annual meeting. The data were from LabGenius’…

May 16, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 12 May 2023

Achilles Therapeutics’ new platform identifies most potent T-cell antigens

Achilles Therapeutics plc says its newly-developed AI application, trained with proprietary real-world data, outperformed current AI and non-AI methods for neoantigen immunogenicity prediction in a recent analysis, enabling the identification…

May 12, 2023 - 3 minutesmins - By Jim Cornall

Fluorescence microcopy image of gamma delta T cells (green) attacking cancer cells (blue). To get tot he cancer cells, the immune cells need to navigate through a dense extracellular matrix that surrounds the tumor tissue (red). Image: Katrin Raute / University of Freiburg

News and Trends 4 May 2023

Osteoporosis drug helps T cells fight aggressive breast cancer

Researchers in Germany have discovered a mechanism by which cancer cells escape the immune system - and how to reverse it. Triple-negative breast cancer (TNBC) is the most aggressive and…

May 4, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 3 May 2023

Eterna acquires allogeneic immuno-oncology platform from Exacis

Eterna Therapeutics Inc. has announced the acquisition of the global immuno-oncology platform of Exacis Biotherapeutics. The acquisition complements Eterna Therapeutics’ core business with a pipeline of allogeneic immuno-oncology products under…

May 3, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 28 Apr 2023

Vitalli Bio formed to focus on immunological disorders

Aditum Bio has announced the formation of Vitalli Bio, a portfolio company created for the development of novel therapies for immunological disorders. Aditum Bio is a biotech investment firm cofounded…

April 28, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 23 Mar 2023

LIfT BioSciences hails breakthrough data for treating solid tumors

LIfT BioSciences has announced what it says are exciting preclinical data demonstrating that its immunomodulatory alpha neutrophil product (IMANp) possesses both cytotoxic and immunomodulatory functionalities. The company said these are commonly…

March 23, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 17 Mar 2023

Likang gets trial ok for China’s first personalized cancer vaccine

Likang Life Sciences has received implied approval for the clinical trial of its personalized neoantigen-targeted vaccine for advanced solid tumors, LK101 injection. This is the first personalized neoantigen vaccine and…

March 17, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 24 Feb 2023

Beyond Biotech podcast 35: Rare Disease Day

As February 28 is Rare Disease Day, we have three guests on the podcast today all relevant to rare diseases. And they are Dan Mandell, CEO and co-founder of GRO…

February 24, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 17 Feb 2023

Positive results for INOVIO recurrent respiratory papillomatosis trial

INOVIO Pharmaceuticals has announced positive preliminary results from the second cohort of its phase 1/2 clinical trial evaluating INO-3107 for the treatment of HPV 6 and HPV 11-associated recurrent respiratory…

February 17, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 16 Feb 2023

Genetic study reveals high variation in T-cell receptor genes

T-cells are central in the protection against infections and cancer. With the help of TCRs (T-cell receptors), cells recognize foreign invaders and tumor cells. “It was previously unknown how variable…

February 16, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 14 Feb 2023

Scancell looking to partner after positive COVID vaccine data

Scancell Holdings plc, which develops novel immunotherapies for the treatment of cancer and infectious disease, has announced preliminary immunogenicity data from its phase 1 COVIDITY clinical trial at the University…

February 14, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 14 Feb 2023

Syena created to deliver first-in-class TCR-NK cell therapy

Replay, a genome writing company reprogramming biology by writing and delivering big DNA, and The University of Texas MD Anderson Cancer Center, have launched Syena, a new oncology-focused product company…

February 14, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 27 Jan 2023

HKUMed uncovers T cell exhaustion factor driving cancer immunotherapy resistance

A research team from the LKS Faculty of Medicine, the University of Hong Kong (HKUMed) has identified an unexpected driver of cancer immunotherapy resistance: the harmful effect of chronic Type…

January 27, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 24 Jan 2023

First leukemia patient dosed with SMART101

Smart Immune has announced that the first adult leukemia patient has been dosed with SMART101, a T-cell progenitor cell injection derived from donor stem cells using ProTcell at Memorial SloanKettering…

January 24, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 3 Jan 2023

Legend Biotech new drug application approved in China

Legend Biotech Corporation has announced that China’s National Medical Products Administration (NMPA) has formally accepted its new drug application (NDA) for ciltacabtagene autoleucel (cilta-cel). This submission is based on data…

January 3, 2023 - 3 minutesmins - By Jim Cornall

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

View all companies A-Z

Find new scientific partnerships. Create a free IN-PART account

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inova, the leading platform for biopharma partnering